Search

Your search keyword '"Hammond, Sarah"' showing total 6 results
Start Over Author "Hammond, Sarah" Journal journal of clinical microbiology
6 results on '"Hammond, Sarah"'

4. Serum Galactomannan and (1?3)-ß-d-Glucan Assays for Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia

Author

Issa, Nicolas C., Koo, Sophia, Lynch, Robert C., Gay, Charline, Hammond, Sarah P., Baden, Lindsey R., Ghobrial, Irene M., Finkelman, Malcolm A., and Marty, Francisco M.

Abstract

ABSTRACTWe assessed the performance of galactomannan and (1?3)-ß-d-glucan in 29 serum samples from patients with multiple myeloma and Waldenstrom's macroglobulinemia without invasive fungal disease to address issues of false positivity and uninterpretable results previously reported among patients with these conditions. Galactomannan and (1?3)-ß-d-glucan assays were not falsely elevated in any patient. (1?3)-ß-d-glucan assay results were uninterpretable in 24% of patients. Patients with IgG levels of >2,000 mg/dl had higher odds of uninterpretable (1?3)-ß-d-glucan results.

Published
2012
Full Text
View/download PDF

5. Serum Galactomannan and (1→3)-β-D-Glucan Assays for Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia

Author

Issa, Nicolas C., Koo, Sophia, Lynch, Robert C., Gay, Charline, Hammond, Sarah P., Baden, Lindsey R., Ghobrial, Irene M., Finkelman, Malcolm A., and Marty, Francisco M.

Abstract

We assessed the performance of galactomannan and (1→3)-β-D-glucan in 29 serum samples from patients with multiple myeloma and Waldenstrom's macroglobulinemia without invasive fungal disease to address issues of false positivity and uninterpretable results previously reported among patients with these conditions. Galactomannan and (1→3)-β-D-glucan assays were not falsely elevated in any patient. (1→3)-β-D-glucan assay results were uninterpretable in 24% of patients. Patients with IgG levels of >2,000 mg/dl had higher odds of uninterpretable (1→3)-β-D-glucan results.

Published
2012

6. Serum galactomannan and (1->3)-β-D-glucan assays for patients with multiple myeloma and Waldenstrom's macroglobulinemia.

Author

Issa NC, Koo S, Lynch RC, Gay C, Hammond SP, Baden LR, Ghobrial IM, Finkelman MA, and Marty FM

Subjects
Adult, Aged, Aged, 80 and over, Female, Galactose analogs & derivatives, Humans, Male, Middle Aged, Multiple Myeloma immunology, Proteoglycans, Serum chemistry, Waldenstrom Macroglobulinemia immunology, Diagnostic Errors, Mannans blood, Multiple Myeloma complications, Mycoses diagnosis, Waldenstrom Macroglobulinemia complications, beta-Glucans blood
Abstract

We assessed the performance of galactomannan and (1→3)-β-d-glucan in 29 serum samples from patients with multiple myeloma and Waldenstrom's macroglobulinemia without invasive fungal disease to address issues of false positivity and uninterpretable results previously reported among patients with these conditions. Galactomannan and (1→3)-β-d-glucan assays were not falsely elevated in any patient. (1→3)-β-d-glucan assay results were uninterpretable in 24% of patients. Patients with IgG levels of >2,000 mg/dl had higher odds of uninterpretable (1→3)-β-d-glucan results.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results